Related Experiment Video

Updated: Aug 12, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure

N Nagaya1, K Miyatake, M Uematsu

  • 1Department of Internal Medicine, National Cardiovascular Center, Suita, Osaka 565-8565, Japan. nagayann@hsp.ncvc.go.jp

The Journal of Clinical Endocrinology and Metabolism
|December 12, 2001
PubMed

Insights

Ghrelin, a growth hormone-releasing peptide, improved hemodynamics in chronic heart failure patients. This peptide enhanced cardiac output and stroke volume without affecting renal function, suggesting potential therapeutic benefits.

Area of Science:

  • Cardiology
  • Endocrinology
  • Nephrology

Background:

  • Ghrelin is a growth hormone-releasing peptide with potential vasodilatory and energy balance effects.
  • The impact of ghrelin on cardiovascular, renal, and hormonal systems in chronic heart failure (CHF) patients is not well understood.

Purpose of the Study:

  • To investigate the hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with CHF.

Main Methods:

  • A randomized, placebo-controlled study involving 12 CHF patients.
  • Intravenous infusion of human ghrelin (0.1 microg/kg.min) or placebo.
  • Monitoring of hemodynamic, renal, and hormonal parameters.

Main Results:

  • Ghrelin significantly decreased mean arterial pressure and increased cardiac index and stroke volume index.
  • Ghrelin markedly increased serum growth hormone (GH) levels and slightly elevated epinephrine, ACTH, cortisol, and prolactin.
  • No significant changes were observed in renal function (urine volume, sodium excretion, creatinine clearance) or pulmonary pressures.

Conclusions:

  • Intravenous ghrelin administration demonstrates beneficial hemodynamic effects in CHF patients.
  • Ghrelin's impact on renal function in CHF is negligible.
  • Ghrelin is a potent GH-releasing peptide with potential therapeutic applications in heart failure management.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.